Omeros (OMER) Stock Forecast & Price Target

Omeros is well-positioned for future success, with a strong and innovative pipeline targeting large-market and orphan indications, including complement-mediated diseases and cancers. The company's recent partnership with Novo Nordisk provides significant milestones and royalties, and a strong U.S. launch for YARTEMLEA has exceeded expectations, with broad formulary access and early metrics indicating positive adoption. While the recent EU setback is disappointing, the company's other assets and partnerships still provide significant upside potential, with a valuation target of $40 based on a risk-adjusted discounted cash flow model and a WACC of 12.5%. However, risks remain, including regulatory, clinical development, commercialization, and intellectual property risks, as well as the success of future pipeline candidates.

Omeros is facing a short-term overhang due to the EU's recommendation against using YARTEMLEA as a first line treatment for TA-TMA, but this decision is not expected to have a significant impact on sales in the long term. The company's financials may also be affected by the slow launch of YARTEMLEA in the EU, but the potential of the drug and its partnership with NVO could still lead to positive outcomes in the future, potentially driving an increase in the stock's value.